Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study

Elias Jabbour(The University of Texas MD Anderson Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Jörge E. Cortes(Augusta University Health), Nitin Jain(Parul University), Marina Konopleva(Albert Einstein College of Medicine), Jeffrey L. Jorgensen(The University of Texas MD Anderson Cancer Center), Koji Sasaki(The University of Texas MD Anderson Cancer Center), Rebecca Garris(The University of Texas MD Anderson Cancer Center), Xuelin Huang(The University of Texas MD Anderson Cancer Center), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Naval Daver(The University of Texas MD Anderson Cancer Center), Joie Alvarez(The University of Texas MD Anderson Cancer Center), Naveen Pemmaraju(The University of Texas MD Anderson Cancer Center), Joseph D. Khoury(University of Nebraska Medical Center), William G. Wierda(University of Maryland, Baltimore), Nicholas J. Short(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Susan O’Brien(University of California, Irvine), Courtney D. DiNardo(The University of Texas MD Anderson Cancer Center)
The Lancet Haematology
November 27, 2018
Cited by 273


Related Papers